Canopy Biosciences and Enable Medicine Announce Partnership to Bring Advanced Spatial Analysis Pipelines to the ChipCytometry Platform
April 12 2023 - 6:00AM
Business Wire
Enable Cloud Platform to be Available with
Canopy CellScape System for High-Plex Spatial Biology
Canopy Biosciences, a Bruker Company, and Enable Medicine, today
announced a partnership to provide Enable Medicine’s advanced
analysis pipelines for spatial omics data with the Canopy
CellScape™ system for quantitative high-plex spatial biology. The
partnership will add to the analytic capabilities of the CellScape
system by providing options to use Enable Medicine’s advanced
spatial analyses, including cluster analysis, neighborhood analysis
and advanced data visualization, as well as efficient cloud-based
computing, sharing, and data storage.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230412005195/en/
Canopy Biosciences’ CellScape instrument
allows for detection and quantification of up to 100 or more
protein targets with 182nm resolution and 8-log high dynamic range
imaging (Photo: Business Wire)
The Canopy CellScape system allows for quantitative, high-plex
spatial proteomics imaging with leading quantitative performance.
Enable Medicine’s Enable Cloud platform accelerates biological
insights via advanced spatial analytics and cloud-based workflows
for spatial biology. Integrating the Enable Cloud Platform into the
CellScape system promises to significantly enhance and streamline
analysis for discovery and translational research applications.
“The CellScape system delivers best-in-class quantitative
spatial proteomics data through our proprietary, 8-log high-dynamic
range (HDR) imaging.” said Thomas Campbell, Ph.D., Group Product
Manager at Canopy Biosciences. “Collaborating with Enable Medicine
allows us to augment our high-plex, high-resolution quantitative
data analysis to provide our researchers with deeper biological
insights.”
“Enable Medicine is committed to accelerating biological
insights by analyzing large and complex spatial biology datasets on
the cloud,” added Aaron Mayer, Co-founder and Chief Scientific
Officer at Enable Medicine. “This partnership combines our
expertise in multiplexed image analysis with Canopy’s high-quality
datasets to advance insights in the field of spatial biology.”
Canopy Biosciences and Enable Medicine will showcase their
integrated data workflow at the American Association for Cancer
Research (AACR) annual meeting in April 2023.
About CellScape Combining an advanced, purpose-built imaging
system with easy-to-use fluidics for walk-away automation, the
CellScape platform enables rapid high-plex spatial omics. The
system uses standard fluorescently labelled antibodies for
detection of targets with open-source reagents, lowering the cost
and decreasing the timeline of assay validation and customization.
With best-in-class resolution and proprietary high dynamic range
(HDR) imaging, CellScape allows for single-cell quantification of
virtually unlimited protein biomarkers in intact tissue samples.
For more information about CellScape, visit
www.canopybiosciences.com/cellscape.
About Canopy Biosciences, a Bruker Company Canopy Biosciences
was formed in 2016 and rapidly built a comprehensive portfolio of
products and services for spatial biology, multi-omics, and
bioprocessing. Canopy offers its ChipCytometry™ technology for
precise spatial multiplexing in cells and tissue samples, along
with other technologies for single-cell RNAseq, bulk RNAseq, and
other gene expression analysis services. Canopy Biosciences is
headquartered in St. Louis, Missouri, with additional sites in
California and Germany to serve researchers at universities,
research institutions, and biotechnology and pharmaceutical
companies worldwide. Canopy was acquired by Bruker Corporation
(Nasdaq: BRKR) in 2020. Additional information is available at
www.canopybiosciences.com.
About Bruker Corporation (Nasdaq: BRKR) Bruker is enabling
scientists to make breakthrough discoveries and develop new
applications that improve the quality of human life. Bruker’s high
performance scientific instruments and high value analytical and
diagnostic solutions enable scientists to explore life and
materials at molecular, cellular and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity and customer success in life science
molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
About Enable Medicine At Enable Medicine, our mission is
to improve the outcomes for patients suffering from serious disease
by building tools that maximize the effectiveness of drug or cell
therapies. To this end, we have developed an end-to-end solution
for interpreting spatial biology that is used by hundreds of
scientists. The Enable platform allows generation of multi-modal
data from patient samples and extraction of translational insights.
The platform empowers users to comprehensively search and
re-interpret a growing knowledge bank composed of petabytes of
spatial-omics data from billions of measurements taken across 500M+
single cells from 20,000+ patients with clinical data. Our complete
images to insights service is based on our cloud-based technology
to escalate discovery of novel insights from research data. De-risk
your clinical development through mechanism of action
determination, biomarker identification, and patient
stratification. At Enable Medicine, we are dedicated to improving
patient outcomes through our cutting-edge technology and innovative
solutions. Learn more about Enable Medicine at
https://www.enablemedicine.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230412005195/en/
Investor: Justin Ward Senior Director, Investor Relations
& Corporate Development T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com
Media: Kevin Gamber Vice President, Marketing and R&D
Canopy Biosciences, A Bruker Company T: +1 (314) 662-9987 E:
kevin.gamber@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024